Literature DB >> 18178412

Usefulness of B-type natriuretic peptide and cardiac troponin levels to predict in-hospital mortality from ADHERE.

Gregg C Fonarow1, William F Peacock, Tamara B Horwich, Christopher O Phillips, Michael M Givertz, Margarita Lopatin, Janet Wynne.   

Abstract

B-type natriuretic peptide (BNP) and cardiac troponin (Tn) I or T have been demonstrated to provide prognostic information in patients with acute coronary syndromes. Whether admission BNP and Tn levels provide additive prognostic value in acutely decompensated heart failure (HF) has not been well studied. Hospitalizations for HF from April 2003 to December 2004 entered into ADHERE were analyzed. BNP assessment on admission was performed in 48,629 (63%) of 77,467 hospitalization episodes. Tn assessment was performed in 42,636 (88%) of these episodes. In-hospital mortality was assessed using logistic regression models adjusted for age, gender, blood urea nitrogen, systolic blood pressure, creatinine, sodium, pulse, and dyspnea at rest. Median BNP was 840 pg/ml (interquartile range 430 to 1,730). Tn was increased in 2,370 (5.6%) of 42,636 HF episodes. BNP above the median and increased Tn were associated with significantly increased risk of in-hospital mortality (odds ratios [OR] 2.09 and 2.41 respectively, each p value <0.0001). Mortality was 10.2% in patients with BNP >or=840/Tn increased compared with 2.2% with BNP <840/Tn not increased (OR 5.10, p <0.0001). After covariate adjustment, mortality risk remained significantly increased with BNP >or=840/Tn not increased (adjusted OR 1.56, 95% confidence interval 1.40 to 1.79, p <0.0001), BNP <840/Tn increased (adjusted OR 1.69, 95% confidence interval 1.17 to 2.45, p = 0.006), and BNP >or=840/Tn increased (adjusted OR 3.00, 95% confidence interval 2.47 to 3.66, p <0.0001). Admission BNP and cardiac Tn levels are significant, independent predictors of in-hospital mortality in acutely decompensated HF. Patients with BNP levels >or=840 pg/ml and increased Tn levels are at particularly high risk for mortality. In conclusion, a multimarker strategy for the assessment of patients hospitalized with HF adds incremental prognostic information.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18178412     DOI: 10.1016/j.amjcard.2007.07.066

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  25 in total

1.  Troponin T levels in patients with acute heart failure: clinical and prognostic significance of their detection and release during hospitalisation.

Authors:  Marco Metra; Luca Bettari; Franca Pagani; Valentina Lazzarini; Carlo Lombardi; Valentina Carubelli; Graziella Bonetti; Silvia Bugatti; Giovanni Parrinello; Luigi Caimi; G Michael Felker; Livio Dei Cas
Journal:  Clin Res Cardiol       Date:  2012-03-10       Impact factor: 5.460

Review 2.  Perspective on the clinical application of troponin in heart failure and states of cardiac injury.

Authors:  Almasa Bass; J Herbert Patterson; Kirkwood F Adams
Journal:  Heart Fail Rev       Date:  2009-04-05       Impact factor: 4.214

Review 3.  Biomarker-guided therapy for heart failure.

Authors:  K Sarat Chandra
Journal:  Indian Heart J       Date:  2012-04-28

Review 4.  Kidney disease in heart failure: the importance of novel biomarkers for type 1 cardio-renal syndrome detection.

Authors:  Alberto Palazzuoli; Peter A McCullough; Claudio Ronco; Ranuccio Nuti
Journal:  Intern Emerg Med       Date:  2015-05-14       Impact factor: 3.397

5.  Short-term effect of levosimendan on free light chain kappa and lambda levels in patients with decompensated chronic heart failure.

Authors:  Ibrahim Halil Kurt; Kemal Yavuzer; Mustafa Kemal Batur
Journal:  Heart Vessels       Date:  2010-07-31       Impact factor: 2.037

6.  Comparison of the utility of preoperative versus postoperative B-type natriuretic peptide for predicting hospital length of stay and mortality after primary coronary artery bypass grafting.

Authors:  Amanda A Fox; Jochen D Muehlschlegel; Simon C Body; Stanton K Shernan; Kuang-Yu Liu; Tjorvi E Perry; Sary F Aranki; E Francis Cook; Edward R Marcantonio; Charles D Collard
Journal:  Anesthesiology       Date:  2010-04       Impact factor: 7.892

7.  Role of Cardiac Troponin Levels in Acute Heart Failure.

Authors:  Nicholas Wettersten; Alan Maisel
Journal:  Card Fail Rev       Date:  2015-10

8.  Timing and duration of interventions in clinical trials for patients with hospitalized heart failure.

Authors:  Catherine N Marti; Gregg C Fonarow; Mihai Gheorghiade; Javed Butler
Journal:  Circ Heart Fail       Date:  2013-09-01       Impact factor: 8.790

Review 9.  Interpretation and use of natriuretic peptides in non-congestive heart failure settings.

Authors:  Shih-Hung Tsai; Yen-Yue Lin; Shi-Jye Chu; Ching-Wang Hsu; Shu-Meng Cheng
Journal:  Yonsei Med J       Date:  2010-02-12       Impact factor: 2.759

Review 10.  Cardiac Biomarkers in Advanced Heart Failure: How Can They Impact Our Pre-transplant or Pre-LVAD Decision-making.

Authors:  Imo Ebong; Sula Mazimba; Khadijah Breathett
Journal:  Curr Heart Fail Rep       Date:  2019-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.